Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $4.50 Average Price Target from Analysts

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have been given a consensus recommendation of “Hold” by the nine analysts that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $3.20.

GOSS has been the topic of several research reports. HC Wainwright decreased their target price on Gossamer Bio from $5.00 to $2.00 and set a “buy” rating on the stock in a research report on Thursday, June 25th. Cantor Fitzgerald reissued a “neutral” rating on shares of Gossamer Bio in a report on Monday, March 23rd. Finally, Weiss Ratings downgraded Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 19th.

Institutional Investors Weigh In On Gossamer Bio

A number of hedge funds and other institutional investors have recently modified their holdings of GOSS. Legal & General Group Plc bought a new stake in shares of Gossamer Bio in the second quarter valued at about $26,000. Banco BTG Pactual S.A. bought a new position in Gossamer Bio during the second quarter worth about $27,000. MMA Asset Management LLC bought a new position in Gossamer Bio during the fourth quarter worth about $31,000. Soltis Investment Advisors LLC acquired a new stake in Gossamer Bio in the 4th quarter worth about $31,000. Finally, Beacon Pointe Advisors LLC acquired a new stake in Gossamer Bio in the 4th quarter worth about $34,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Stock Performance

Shares of GOSS stock opened at $0.14 on Tuesday. The company has a market capitalization of $33.82 million, a price-to-earnings ratio of -0.18 and a beta of 2.04. The company has a 50-day simple moving average of $0.21 and a 200 day simple moving average of $1.00. Gossamer Bio has a 52 week low of $0.14 and a 52 week high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The company had revenue of $16.95 million for the quarter, compared to analyst estimates of $4.67 million. Sell-side analysts forecast that Gossamer Bio will post -0.37 EPS for the current year.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.